Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 24, 2026

Fast Company Unveils 2026 Most Innovative Companies List, Led by Google, Nvidia, and Shopify

View original at finance.yahoo.com
Fast Company Unveils 2026 Most Innovative Companies List, Led by Google, Nvidia, and Shopify Fast Company 720 honorees across 59 categories are recognized as the companies delivering true innovation and value for businesses, consumers, and the world in the AI era Fast Company Most Innovative Companies Cover Featuring G…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is a growing tension between innovation that creates new value and innovation that simply extracts it—a balance that will define the next era of business

    60% confidence

  • What stands out from the thousands of companies we evaluated in 2026 is how innovation is increasingly about the enduring power of human creativity

    60% confidence

  • What stands out from the thousands of companies evaluated in 2026 is how innovation is increasingly about the enduring power of human creativity

    60% confidence

  • We're seeing a growing tension between innovation that creates new value and innovation that simply extracts it—a balance that will define the next era of business

    60% confidence

Data points we hold from this source

Shopify Inc. · ranking3 rank
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com